Commentary | Published:

Stem cells—a hard sell to investors

Subjects

A lack of proven commercial success and a surfeit of ethical, legal and political problems make stem cell companies a difficult pitch to venture capitalists.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Author information

Rights and permissions

To obtain permission to re-use content from this article visit RightsLink.

About this article

Further reading

Figure 1: Market performance of 5 'stem cell' companies illustrates the volatility of the group compared with the Nasdaq general biotech stock index.